Studies highlight the company’s ongoing commitment to advancing care for patients with myeloid malignancies PRINCETON, N.J., Dec. 9, 2024 /PRNewswire/…
R289 was generally well tolerated and demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patients RBC-TI/HI-E responses…
Data provide support for planned expanded clinical development of best-in-class RGT-61159 in MYB-dependent hematologic cancers, including AML Potent anti-tumor activity observed,…